CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer

International Journal of Cancer

Volumn 128, Issue 5, 2011, Pages 1009-1017

  Koga, Takaomi ^a   Takeshita, Masafumi ^a   Yano, Tokujiro ^a   Maehara, Yoshihiko ^a   Sueishi, Katsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

CHFR; EGFR; hypermethylation; mutation; smoking

Indexed keywords

CHECKPOINT GENE WITH FORKHEAD ASSOCIATED DOMAIN AND RING FINGER GENE; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CODON; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; EXON; FEMALE; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; DNA METHYLATION; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 78650728084     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25447     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC,. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
3. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-55. (Pubitemid 40812628)
4. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T,. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-23.
5. Mitsudomi T, Yatabe Y,. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98: 1817-24.
6. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26: 1472-8.
7. Takeshita M, Koga T, Takayama K, Kouso H, Nishimura-Ikeda Y, Yoshino I, Maehara Y, Nakanishi Y, Sueishi K,. CHFR expression is preferentially impaired in smoking-related squamous cell carcinoma of the lung, and the diminished expression significantly harms outcomes. Int J Cancer 2008; 123: 1623-30.
8. Scolnick DM, Halazonetis TD,. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 2000; 406: 430-5.
9. Chaturvedi P, Sudakin V, Bobiak ML, Fisher PW, Mattern MR, Jablonski SA, Hurle MR, Zhu Y, Yen TJ, Zhou BB,. Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res 2002; 62: 1797-1801.
10. Kang D, Chen J, Wong J, Fang G,. The checkpoint protein Chfr is a ligase that ubiquitinates PLK1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol 2002; 156: 249-59.
11. Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, Mita H, Tanaka N, Itoh F, Issa JP, Jair KW, Schuebel KE, et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA 2003; 100: 7818-23.
12. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD, El-Deiry WS,. Frequent hypermethylation of the 5â CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non small cell lung cancer. Carcinogenesis 2003; 24: 47-51.
13. Shibata Y, Haruki N, Kuwabara Y, Ishiguro H, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Nishiwaki T, Kudo J, Terashita Y, et al. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis 2002; 23: 1695-9.
14. Kobayashi C, Oda Y, Takahira T, Izumi T, Kawaguchi K, Yamamoto H, Tamiya S, Yamada T, Iwamoto Y, Tsuneyoshi M,. Aberrant expression of CHFR in malignant peripheral nerve sheath tumors. Mod Pathol 2006; 19: 524-32.
15. Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, Fujii Y, Takahashi T,. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 2002; 21: 2328-33.
16. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ, Ward IM, Saya H, Fang G, van Deursen J, Chen J,. Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 2005; 37: 401-6.
17. Privette LM, González ME, Ding L, Kleer CG, Petty EM,. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: Implications for tumor suppression. Cancer Res 2007; 67: 6064-74.
18. Koga T, Hashimoto S, Sugio K, Yoshino I, Mojtahedzadeh S, Matsuo Y, Yonemitsu Y, Sugimachi K, Sueishi K,. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. Clin Cancer Res 2001; 7: 1730-8.
19. Koga T, Hashimoto S, Sugio K, Yoshino I, Nakagawa K, Yonemitsu Y, Sugimachi K, Sueishi K,. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation. Int J Cancer 2001; 95: 232-9.
20. Mountain CF,. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
21. Chomczynski P, Sacchi N,. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
22. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
23. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
24. Oh YM, Kwon YE, Kim JM, Bae SJ, Lee BK, Yoo SJ, Chung CH, Deshaies RJ, Seol JH,. Chfr is linked to tumour metastasis through the downregulation of HDAC1. Nat Cell Biol 2009; 11: 295-302.
25. Kashima L, Toyota M, Mita H, Suzuki H, Idogawa M, Ogi K, Sasaki Y, Tokino T,. CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappaB. Oncogene 2009; 28: 2643-53.
26. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65: 1642-6.
27. Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K, Sugimachi K,. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer 1997; 75: 1125-30.
28. Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM, McCormick F,. PIK3CA cooperates with other phosphatidylinositol 3â-kinase pathway mutations to effect oncogenic transformation. Cancer Res 2008; 68: 8127-36.
29. Shopland DR,. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect 1995; 103: 131-42.
30. Zochbauer-Muller S, Gazdar AF, Minna JD,. Molecular pathogenesis of lung cancer. Annu Rev Physiol 2002; 64: 681-708.
31. Liu Y, Lan Q, Siegfried JM, Luketich JD, Keohavong P,. Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 2006; 8: 46-51.
32. Jarmalaite S, Kannio A, Anttila S, Lazutka JR, Husgafvel-Pursiainen K,. Aberrant p16 promoter methylation in smokers and former smokers with non-small-cell lung cancer. Int J Cancer 2003; 106: 913-8.
33. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG,. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95: 11891-6.
34. Tsukamoto S, Sugio K, Sakada T, Ushijima C, Yamazaki K, Sugimachi K,. Reduced expression of cell-cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer. Lung Cancer 2001; 34: 83-90.
35. Bennett WP, el-Deiry WS, Rush WL, Guinee DG Jr., Freedman AN, Caporaso NE, Welsh JA, Jones RT, Borkowski A, Travis WD, Fleming MV, Trastek V, et al. p21waf1/cip1 and transforming growth factor β1 protein expression correlate with survival in non-small-cell lung cancer. Clin Cancer Res 1998; 4: 1499-506.
36. Ji Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K, Kato H,. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001; 34: 207-18.
37. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM,. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small-cell lung cancer: a review. Clin Cancer Res 2005; 11: 3974-86.